HIF1A and neoplasm: Anti-angiogenesis therapy, such as bevacizumab treatment, has an indirect effect on tumor cells as described above but leads to the activation of the hypoxia HIF-1α program resulting in the upregulation of drug resistance pathways [62, 63, 93].